Biotech Values

[Titan V]

ARRY(+13%) melanoma drugs show significant survival vs Roche drug in study
https://www.reuters.com/article/us-array-biopharma-melanoma/array-melanoma-drugs-show-significant-survival-vs-roche-drug-in-study-idUSKBN1FQ1U2

A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late stage study released on Tuesday.

The oral drugs, encorafenib and binimetinib, are awaiting a U.S. approval decision by June 30 based on promising data on their ability to stall disease worsening, or progression-free survival (PFS). European regulators are also reviewing the treatment.

However, overall survival is seen as the gold standard for cancer treatments and the new data is likely to significantly enhance approval and eventual sales prospects.